Blte.Ns
BLTE.NS operates in the entertainment production industry, generating revenue primarily through the creation and distribution of entertainment content.
Business. BLTE.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BLTE.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
BLTE.NS maintains a strong liquidity position with a current ratio of 3.73, indicating the company can cover its short-term liabilities more than three times over. However, the company's cash and equivalents amount to only INR 160,000, which is significantly lower than its total liabilities of INR 1,439,525,000, suggesting potential liquidity constraints despite the favorable current ratio. The company's debt-to-equity ratio is 0.01, reflecting a conservative capital structure with minimal reliance on debt financing.
In terms of profitability, BLTE.NS reported a net income of INR 870,803,000 and a return on equity of 13.25%, which is a strong return relative to the company's equity base. The return on assets of 10.87% also indicates efficient use of assets to generate profit. These metrics suggest that the company is performing well compared to industry standards, although specific industry medians are not provided in the data.
BLTE.NS operates as a single entity without disclosed segments, and its geographic exposure is not specified in the available data. The company's revenue concentration is not detailed, but the absence of segment reporting implies that it may not have significant geographic or product diversification.
The company's growth trajectory is not explicitly outlined in the data, but the operating cash flow of INR 517,292,000 and free cash flow of INR 878,782,000 indicate positive cash generation. These figures suggest the company has the capacity to fund operations and potentially invest in growth opportunities. However, the capital expenditure of INR -42,309,000 indicates a reduction in capital spending, which could affect future growth.
BLTE.NS faces a medium liquidity risk, as noted in the risk assessment, and a low dilution risk. The company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations without additional financing. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics, suggesting that the company's financial structure is stable.
Recent events and filings are not detailed in the provided data, so no specific recent developments can be cited. The company's financial health appears to be supported by strong profitability and a conservative capital structure, but the low cash reserves and negative net cash position warrant monitoring for potential liquidity issues.
- BLTE.NS has a strong return on equity of 13.25%, indicating efficient use of shareholder funds.
- The company maintains a conservative capital structure with a debt-to-equity ratio of 0.01.
- Despite a favorable current ratio, the company's cash and equivalents are significantly lower than its liabilities.
- BLTE.NS generates positive operating and free cash flows, suggesting strong cash generation capabilities.
- The company faces medium liquidity risk and a low dilution risk, with a negative net cash position after debt.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Medical Officer · Stock Option (right to buy) → Ordinary SharesAcquired 10 000 @ $77,40other · 2026-04-21
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BLTE.NS Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$123M
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$32M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$3M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Yu-Hsin LinChairman of the Board, Chief Executive Officer
Insider activity
- Chief Medical Officer · American depositary shareSold 96 @ $143,90$14K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 3 748 @ $144,66$542K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 4 861 @ $145,43$707K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 1 199 @ $146,24$175K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 96 @ $147,11$14K · 2026-06-18
- Chief Medical Officer · American depositary shareSold 540 @ $140,58$76K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 2 054 @ $137,61$283K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 784 @ $138,18$108K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 3 140 @ $139,57$438K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 100 @ $141,83$14K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 450 @ $142,20$64K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 1 897 @ $143,55$272K · 2026-06-16
- Chief Medical Officer · American depositary shareSold 1 035 @ $145,02$150K · 2026-06-16
- Chief Scientific Officer · American depositary shareSold 9 @ $155,25$1K · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 428 @ $153,56$66K · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 3 @ $154,61$464 · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 226 @ $152,45$34K · 2026-05-07
- Chief Scientific Officer · American depositary shareSold 240 @ $154,41$37K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 100 @ $155,97$16K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 424 @ $152,67$65K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 8 @ $151,57$1K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 100 @ $156,00$16K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 128 @ $153,42$20K · 2026-05-06
- Chief Scientific Officer · American depositary shareSold 121 @ $156,53$19K · 2026-05-05
- Chief Scientific Officer · American depositary shareSold 120 @ $153,92$18K · 2026-05-05
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -26.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -95.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -114.7%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -38.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -95.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,014.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 59.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 413.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 428.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 51.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -110.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -10.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -9.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 50.02xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.01xDerived (calculated)
- Pre-tax income (annual): USD -77.61MSEC XBRL filing
- Total operating expenses (annual): USD 84.21MSEC XBRL filing
- Capex (annual): USD 71KSEC XBRL filing
- Cash & equivalents (annual): USD 352.93MSEC XBRL filing
- Current liabilities (annual): USD 9.88MSEC XBRL filing
- Current assets (annual): USD 494.27MSEC XBRL filing
- Shareholders' equity (annual): USD 770.49MSEC XBRL filing
- Shares outstanding (annual): 39.34MSEC XBRL filing
- Total liabilities (annual): USD 10.07MSEC XBRL filing